Bronchiolitis Obliterans
Conditions
Keywords
induced Sputum, lung clearance index, miRNA, inflammation, chronic lung disease
Brief summary
Bronchiolitis obliterans is a chronic disease in which a persistent inflammatory process leads to obliteration of the small airways. Pulmonary function tests (body plethysmography with DLCO, lung clearance index) are performed and the fraction of exhaled nitric oxide is measured. A blood test is following to determine the inflammatory status und collect miRNA. Induced Sputum will be obtained.
Detailed description
The purpose of this study is to compare miRNA pattern, lung function values, bronchial inflammation and the Lung clearance index of Patients with Bronchiolitis obliterans aged between 6 up to 30 years of age with a matched control group. The sputum samples will be processed and quantitatively analyzed to get a profile of the cytological composition. Sputum and serum samples are analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) and by cytometric bead assay (CBA). miRNA samples will be collected, processand compared with the miRNA database at http://www.mirbase.org/ Methods and Work Programme: * Measurement of nitric oxide in expired air (FeNO) * Lung function testing with spirometry and body plethysmography * Lung clearance index (LCI) * Bronchodilation * Blood test: blood count, CRP, RAST, serum inflammatory mediators, (genetic markers of the non-specific pulmonary defense system), miRNA analysis * Induced sputum for inflammatory mediators and microbiological investigations
Interventions
OTHERobservation
Record lung function, Lung clearance index, inflammatory status
Sponsors
Johann Wolfgang Goethe University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* informed consent * age between 6 an 35 years * known bronchiolitis obliterans (Group Bronchiolitis)/ no Bronchiolitis Obliterans (Group matched controls) * ability to perform lung function tests and inhale correctly
Exclusion criteria
* \<6 years of age * \>35 years of age * acute systemic or bronchial inflammation * other chronic diseases or infection (e.g. HIV, Tbc, malignoma) * pregnancy * alcohol, drug or illegal drug abuse * disability to register the range and consequences of the study * actual participation in another study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| miRNA Status | single day observation | Blood sample to determine candidate miRNA for Bronchiolitis obliterans |
Other
| Measure | Time frame | Description |
|---|---|---|
| FVC [%-pred.] | single day observation | Compare FVC \[%-pred.\] of BO Patients with a healthy control group |
| FEV1 [%-pred.] | single day observation | Compare FEV1\[%-pred.\] of BO Patients with a healthy control group |
| Tiffeneau Index | single day observation | Compare Tiffeneau-Index of BO Patients with a healthy control group |
| sRtot [%-pred.] | single day observation | Compare sRtot\[%-pred.\] of BO Patients with a healthy control group |
| RV/TLC [%-pred.] | single day observation | Compare RV/TLC\[%-pred.\] of BO Patients with a healthy control group |
| DLCO [%-pred.] | single day observation | Compare difffusion capacity of the lung for CO \[%-pred.\] of BO Patients with a healthy control group |
| Lung clearance index (LCI) | single day observation | Determine Lung clearance index with the Oxygen washout method |
| IL-8 (pg/ml | single day observation | Comparing IL-8 in Serum of patients with BO with a healthy control group |
| Il-17 (pg/ml) | single day observation | Comparing IL-17 in Serum of patients with BO with a healthy control group |
| CrP (mg/dl) | single day observation | Comparing CrP in Serum of patients with BO with a healthy control group |
| FeNO ppb | single day observation | Comparing FeNO in exhaled air of patients with BO with a healthy control group |
| Sputum cell count | single day observation | Comparing sputum cell counts of patients with BO with a healthy control group |
| IL-6 (pg/ml) | single day observation | Comparing IL-6 in Serum of patients with BO with a healthy control group |
Countries
Germany
Contacts
Primary ContactMartin Rosewich, MD
Outcome results
None listed